DIA Bioventure Day

Is the current Bioventure paradigm delivering return for patients and investors? This is the key question to be addressed by stakeholders from the funding, and from the innovating side.

戻る Agenda

Immuno-Oncology: Therapeutic Break Through Area or Nightmare for Health Care Funding

Session Chair(s)

Duane Schulthess, MBA

Chief Executive Officer

Vital Transformation LLC, United States

DIA Bioventure Day

Immuno-Oncology: Therapeutic Break Through Area or Nightmare for Health Care Funding

Session Chair(s)

Duane Schulthess, MBA

最新情報や機会を逃さないで